Kelun─Biotech's TROP2 ADC sacituzumab tirumotecan receives China NMPA marketing approval for 2L+ advanced or metastatic ...
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., a holding subsidiary of Kelun Pharmaceutical, which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs, announced that …